Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Paragon Banking trims mortgage lending outlook despite strong deposit growth

(Sharecast News) - Specialist bank Paragon Banking posted a solid Q3 trading update on Tuesday, with deposit growth buoyed by the launch of its new Spring app, but warned that FY mortgage lending advances would likely be at the lower end of previous guidance. Paragon said loan balances were up 4.8% year-on-year, while deposits grew thanks to a strong showing from its Spring app - the performance of which exceeded expectations, pushing retail savings up 1.5% and earning top-tier customer feedback.

The FTSE 250-listed firm said mortgage advances hit £1.1bn for the nine months ended 30 June, slightly ahead of the prior year, although it noted that stamp duty disruption weighed on completions.

Paragon said its buy-to-let pipeline surged 27.6% from March, while commercial lending volumes rose 6.6%, and net repayments on structured credit dragged total advances down 1.5%. Arrears ticked up slightly in buy-to-let, while legacy development loans continued to necessitate impairments.

While Paragon's FY guidance remained largely unchanged, mortgage lending advances were now expected to come to roughly £1.6bn, which was at the lower end of its previous £1.6bn to £1.8bn guidance.

Chief executive Nigel Terrington said: "The nine months to June 2025 have seen another strong trading period for the group, with loan balances up 4.8% from Q3 2024 and deposit growth supported by the take-up of our new Spring App.

"The momentum in our business and the resilience of our business model means we are well-positioned to continue supporting our customers and delivering strong returns for our shareholders."

As of 1020 BST, Paragon shares had slumped 9.77% to 859.00p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.